Her2-positive breast cancer Trials in Houston, United States
Conditions / Her2-positive breast cancer / Houston, United States
Research into Her2-positive breast cancer spans multiple therapeutic approaches and trial phases.
29 total trials for this combination
Showing top 10 of 29 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT03602079 | Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene | COMPLETED | PHASE1/PHASE2 |
| NCT04106167 | Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy | TERMINATED | — |
| NCT05705401 | Testing Radiation and HER2-targeted Therapy Versus HER2-targeted Therapy Alone for Low-risk HER2-positive Breast Cancer | ACTIVE_NOT_RECRUITING | — |
| NCT05705401 | Testing Radiation and HER2-targeted Therapy Versus HER2-targeted Therapy Alone for Low-risk HER2-positive Breast Cancer | ACTIVE_NOT_RECRUITING | — |
| NCT01042379 | I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer | RECRUITING | PHASE2 |
| NCT04660929 | CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors | ACTIVE_NOT_RECRUITING | PHASE1 |
| NCT04585750 | The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) | RECRUITING | PHASE1/PHASE2 |
| NCT03841110 | FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors | COMPLETED | PHASE1 |
| NCT04893109 | ATEMPT 2.0: Adjuvant T-DM1 vs TH | RECRUITING | — |
| NCT02213744 | MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients | TERMINATED | PHASE2/PHASE3 |